Skip to main content
. Author manuscript; available in PMC: 2021 Jul 28.
Published in final edited form as: ACS Nano. 2020 Jun 23;14(7):8392–8408. doi: 10.1021/acsnano.0c02509

Figure 6. HMC-FMX targets patient-derived GBM CSCs and CSC-derived orthotopic GBM tumors in mice.

Figure 6.

GBM CSC spheroids fluorescently labeled with HMC-FMX (a). Accumulation of HMC-FMX in orthotopic GBM tumor xenografts from U-87 and GBM CSCs (b). Arrow indicates cell injection site. Migration distance for U-87 and GBM CSC-derived tumors from injection site (c). Brightfield, merged brightfield/NIRF and H&E staining of GBM CSC-derived tumors before (d) and after fluorescence image-guided resection (e).